Navigation Links
NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinson's Disease
Date:6/1/2010

NESS ZIONA, Israel, June 1, 2010 /PRNewswire/ -- NeuroDerm, Ltd. announced today the successful enrollment and dosing in its Phase I clinical trial of ND0611. ND0611, a proprietary drug formula administered via a dermal patch, is designed to maintain continuous therapeutic levodopa concentrations for improving the treatment of Parkinson's disease.

ND0611 increases levodopa bioavailability and extends its effects by administering a novel pharmaceutical. Previous animal studies found that ND0611 modified levodopa pharmacokinetics by (i) increasing levodopa plasma half-life and area-under-the-curve (AUC), (ii) maintaining levodopa plasma concentrations in a typical therapeutic range, and (iii) extending dopaminergic stimulation in the brain. ND0611's mode of action involves an under-exploited levodopa metabolic pathway and has the potential for markedly improving clinical benefits from levodopa (the most effective drug for Parkinson's disease).

This Phase 1 study was conducted in healthy volunteers with the purpose of measuring the safety and tolerability of ND0611 at different doses. Further analysis will be completed to determine the pharmacokinetic profile of levodopa in plasma. The company expects to present the results of this phase 1 study in the second half of 2010.

"The completion of this first step in the clinical development of ND0611 marks an important milestone in the path to develop a new therapeutic alternative for Parkinson's disease patients," said Oded S. Lieberman, PhD, NeuroDerm's Chairman and CEO. "While constant levodopa plasma concentrations achieved through continuous levodopa infusion have been shown to bring significant benefit to Parkinson's patients, these options are generally impractical. In contrast, ND0611
'/>"/>

SOURCE NeuroDerm Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
2. MedAvante Opens Moscow Office and Successfully Completes First Centralized Ratings Assessment
3. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
4. Sanofi-aventis Successfully Completes The Acquisition of Chattem, Inc.
5. Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc.
6. Phonak Successfully Hosts Hearing Care for Adults 2009 Conference
7. Tamaulipas Comparative Wound Healing Test Treatment Successfully Concluded
8. DBMS Consulting Successfully Completes Roll out of Oracle Health Sciences Applications (OHSA) Suite for SIRO Clinpharm
9. Guided Delivery Systems, Inc. Successfully Treats First Patient with Mitral Regurgitation
10. Hoviones TwinCaps(R) Inhaler Delivers Successfully in Phase III Clinical Trials for Influenza
11. American University of Beirut Medical Team Successfully Performs First Artificial Heart Implant in Lebanon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... and BOSTON , January 23, 2015 ... discovery and development company, is delighted to announce that the ... awarded to Miles Congreve (Vice President of Chemistry), ... Malcolm Weir (Chief Executive Officer and co-founder) for ...
(Date:1/22/2015)... privately held medical device company, announced today that it ... Corporation (Tokyo Stock Exchange TYO: 8001) to sell its ... in Japan . ViewRay,s technology, the ... MRI-guided radiation therapy system that images and treats cancer ...
(Date:1/22/2015)... UPI ), a medical device company that develops, ... dysfunctions, today reported financial results for the fiscal 2015 ... for the Company,s Urgent ®  PC Neuromodulation System grew ... as compared to $3.9 million in the third quarter ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
... 2011 Niiki Pharma announced today that it will ... study for its lead product, NKP-1339, at the 2011 ... NKP-1339 is a novel transferrin targeted ruthenium based anti-cancer ... key regulator of mis-folded protein processing. In preclinical studies, ...
... On August 1-3, 2011, coinciding with National Convenient ... the Convenient Care Association will present the 4th annual ... the Gaylord Palms hotel in Orlando, Fla. ... education conference designed specifically for the growing field of ...
Cached Medicine Technology:Novel First-in-Class Anti-Cancer Agent in Development by Niiki Pharma Shows Promising Phase I Results 22011 Retail Clinician Education Congress to Offer Exclusive Accreditation and Networking Opportunities for Retail Healthcare Professionals 2
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) wants ... “Live Fearless.” , The “Faces of Fearless” campaign ... how they or someone they know has faced a challenge, ... moment. By telling these types of stories through livefearlessmn.com, participants ...
(Date:1/22/2015)... Florida (PRWEB) January 22, 2015 Juvent ... today at the 2015 PGA Merchandise Show to bestow ... and incredible female amateur golfer, Arlene McKitrick. The award ... female amateur golf tournament win. She won her first ...
(Date:1/22/2015)... 2015 Autocarinsurancebest.com has released a new blog ... auto insurance policy . , Auto insurance quotes help ... is no longer necessary to call an agent or visit ... online on a single website: http://autocarinsurancebest.com/ . , Every ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television ... 32nd Annual Miami Breast Cancer Conference planned ... (PER®) , shares that “a fast-growing, virulent” cancer in ... had not followed up her clean mammogram with an ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... January 13, 2011Twenty years of mortality data from counties across ... at higher altitudes may be a risk factor for suicide, ... in High Altitude Medicine & Biology , a peer-reviewed ... available free online. Barry Brenner, MD, PhD, and ...
... Ohio New research shows that oncolytic viruses, which ... effective in treating deadly brain tumors if equipped with ... enzyme, called chondroitinase, helps the cancer-killing virus clear its ... space between cells and impede the virus,s movement through ...
... Liverpool-led consortium has received $1.5million from the Bill & ... serious disease and epidemics in sub-Saharan Africa. Streptococcus ... in sub-Sahara Africa. The funding will enable scientists ... associated with invasive pneumococcal disease, why it spreads so ...
... (HealthDay News) -- Fall screening and prevention should be a ... programs to prevent falls should include exercise, according to updated ... of the American Geriatrics Society and British Geriatric Society recommendations ... appears Jan. 13 in the Journal of the American ...
... U.S. population, medical expenditures for cancer in the year 2020 ... dollars) an increase of 27 percent over 2010, according ... tools for cancer diagnosis, treatment, and follow-up continue to be ... as $207 billion, said the researchers from the National Cancer ...
... HealthDay Reporter , WEDNESDAY, Jan. 12 (HealthDay News) ... short-term increase in anxiety after receiving the results, whether they ... make any lifestyle changes or get screening tests that might ... according to a study in the Jan. 13 issue of ...
Cached Medicine News:Health News:Virus might fight brain tumors better if armed with bacterial enzyme, study shows 2Health News:Liverpool receives $1.5M to tackle disease in Africa 2Health News:Falls as Serious for Elderly as Stroke, Heart Attack: Experts 2Health News:Cancer costs projected to reach at least $158 billion in 2020 2Health News:Cancer costs projected to reach at least $158 billion in 2020 3Health News:Consumer Genetic Testing May Not Boost Users' Anxiety 2Health News:Consumer Genetic Testing May Not Boost Users' Anxiety 3
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Portless Sheath Introducers...
Introducer Sheath Designed for Vascular Access...
Used to introduce balloon, electrode, closed or non-tapered end and,other catheters....
Medicine Products: